RANI
Rani Therapeutics Holdings Inc
NASDAQ: RANI · HEALTHCARE · BIOTECHNOLOGY
$0.94
+5.87% today
Updated 2026-05-01
Market cap
$108.42M
P/E ratio
—
P/S ratio
66.39x
EPS (TTM)
$-0.45
Dividend yield
—
52W range
$0 – $4
Volume
1.1M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B4.5
Quality
C2.5
Profitability
F6.7
Valuation
B3/9
Piotroski F-Score
Weak
-7.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$7.40
+687.23%
12-Month target
—
—
Intrinsic (DCF)
$3.37
Margin of safety
+62.91%
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $294000.00 — positive
+ Revenue growth 42.10% QoQ
+ 62.91% below intrinsic value
+ Debt/equity -2.23x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -6.95 — distress zone
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.03M | $1.63M | $1.63M |
| Net income | $-30.59M | $-33.97M | $-30.02M | $-29.67M | $-10.31M |
| EPS | — | — | — | — | $-0.45 |
| Free cash flow | $-48.13M | $-52.47M | $-35.76M | $-18.80M | $294000.00 |
| Profit margin | — | — | -2,920.04% | -1,817.09% | — |
Peer comparison
Smart narrative
Rani Therapeutics Holdings Inc trades at $0.94. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.95, it sits in the distress. TTM revenue stands at $1.63M. Our DCF model estimates intrinsic value at $3.37.
Frequently asked questions
What is Rani Therapeutics Holdings Inc's stock price?
Rani Therapeutics Holdings Inc (RANI) trades at $0.94.
Is Rani Therapeutics Holdings Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell). DCF value $3.37.
What is the price target of Rani Therapeutics Holdings Inc (RANI)?
The analyst target price is $7.40, representing +687.2% upside from the current price of $0.94.
What is the intrinsic value of Rani Therapeutics Holdings Inc (RANI)?
Based on our DCF model, intrinsic value is $3.37, a +62.9% margin of safety versus $0.94.
What is Rani Therapeutics Holdings Inc's revenue?
TTM revenue is $1.63M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-6.95 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio66.39x
ROE-182.00%
Beta0.66
50D MA$1.10
200D MA$1.10
Shares out0.10B
Float0.06B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—